Clinical Trial Update: LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial update reports completion of a Phase 1 study evaluating LY3214996 in combination with abemaciclib for recurrent glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioma

Drugs mentioned

• Abemaciclib (abemaciclib)
• LY3214996

Snippet

Sponsor: Nader Sanai | Conditions: Glioblastoma, GBM | EARLY_Phase 1 | Status: COMPLETED